SCHEMBL4309229

SCHEMBL4309229

COCCc1nc2cnc3cccnc3c2n1CCCCNC(=O)OC(C)(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STING1 Q86WV6 4/20 0.46
CYP3A4 P08684 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
GAA P10253 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
KDM4E B2RXH2 2/20 0.42
MAPT P10636 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
BRD4 O60885 1/20 0.42
DRD2 P14416 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
RAB9A P51151 1/20 0.40
ATM Q13315 1/20 0.40
HTT P42858 1/20 0.40
RECQL P46063 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4147523 0.95 GAA (0.43) STING1CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL3355952 0.90 TLR7 (0.48) STING1CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL5124567 0.89 STING1 (0.46) STING1CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL5129239 0.89 STING1 (0.46) STING1CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL2743673 0.88 STING1 (0.45) STING1GAAMEN1KMT2AMAPT
SCHEMBL1231989 0.87 KDM4E (0.45) STING1CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4316046 0.86 TLR7 (0.49) STING1CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL3353897 0.86 TLR7 (0.47) STING1CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL4156877 0.86 KDM4E (0.44) STING1CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL12888449 0.86 KDM4E (0.44) STING1CYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8846710-B2 Method of preferentially inducing the biosynthesis of interferon 3M INNOVATIVE PROPERTIES COMPANY (US) 2014-09-30 US disclosed
US-20090030031-A1 Method of Preferentially Inducing the Biosynthesis of Interferon COLEY PHARMACEUTICAL GROUP, INC. (US) 2009-01-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030031-A1 Method of Preferentially Inducing the Biosynthesis of Interferon IFNG, IFNAR1, EIF2AK2 STING1 5/4885CYP3A4 238/4885CYP2D6 278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.